Myelofibrosis
📧 Sign up to get email alerts when something new happens for Myelofibrosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-12-12Clinical Trial Update: A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets [Phase 1]
The Phase 1 study evaluating drug-drug interactions of TQ05105 tablets has completed.
-
CLINICAL_TRIALS trial_result · 2025-12-10Clinical Trial Update: A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib [Phase 2]
This clinical trial update describes a Phase 2 rollover study of Itacitinib to provide continued treatment for participants previously enrol…
-
CLINICAL_TRIALS trial_result · 2025-10-27Clinical Trial Update: P1101 in Treating Patients With Myelofibrosis [Phase 2]
A Phase 2 trial of P1101 for primary and secondary myelofibrosis has been terminated. Results from the trial were posted on 2025-10-27.
-
CLINICAL_TRIALS trial_result · 2025-10-21Clinical Trial Update: A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) [Phase 1, Phase 2]
A Phase 1/2 clinical trial update describes fedratinib in Japanese patients with DIPSS-intermediate/high-risk primary myelofibrosis, post-po…
-
CLINICAL_TRIALS trial_result · 2025-10-08Clinical Trial Update: A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating CPI-0610 with and without ruxolitinib in patients with hematologic and myeloproliferative malignancies. …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-10-01Clinical Trial Update: Safety of Flonoltinib Maleate Tablets for the Treatment of Patients With Myeloproliferative [Phase 1, Phase 2]
This clinical trial update reports safety findings from Phase 1/2 studies of Flonoltinib Maleate Tablets in patients with myeloproliferative…
-
CLINICAL_TRIALS trial_result · 2025-09-22Clinical Trial Update: An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005) [Phase 2]
Extension-phase update for bomedemstat (IMG-7289/MK-3543) in myeloproliferative neoplasms. The Phase 2 extension study in essential thromboc…
-
CLINICAL_TRIALS trial_result · 2025-08-29Clinical Trial Update: Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis [Phase 2]
Phase 2 trial results report long-term safety and side effects of ruxolitinib in patients with myelofibrosis.
-
CLINICAL_TRIALS trial_result · 2025-08-29Clinical Trial Update: TQ05105 Tablet for Myelofibrosis Treatment in Ruxolitinib-Resistant or Intolerant Patients [Phase 1]
Phase 1 study of TQ05105 tablet for myelofibrosis in patients resistant or intolerant to ruxolitinib has been terminated.
-
CLINICAL_TRIALS trial_result · 2025-08-24Clinical Trial Update: To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Renal Impairment Subjects [Phase 1]
Phase 1 trial evaluating the pharmacokinetics and safety of TQ05105 tablets in renal-impairment subjects with myelofibrosis; the study has c…
-
CLINICAL_TRIALS trial_result · 2025-08-24Clinical Trial Update: Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis [Phase 1, Phase 2]
This update reports on a completed Phase 1/2 study evaluating the safety, pharmacokinetics, pharmacodynamics, and dose expansion of PXS-5505…
-
CLINICAL_TRIALS trial_result · 2025-08-13Clinical Trial Update: P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk [Phase 3]
A Phase 3 clinical trial evaluating P1101 in patients with early or overt primary myelofibrosis at low or intermediate-1 risk is currently r…
-
CLINICAL_TRIALS trial_result · 2025-08-07Clinical Trial Update: Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients [Phase 1, Phase 2]
A platform phase 1/2 study evaluating novel ruxolitinib combinations in myelofibrosis has been terminated; results from the study have been …
-
CLINICAL_TRIALS trial_result · 2025-07-29Clinical Trial Update: Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis. [Phase 2]
A Phase 2 clinical trial conducted at Massachusetts General Hospital evaluated ruxolitinib given before, during, and after allogeneic stem c…
-
CLINICAL_TRIALS trial_result · 2025-07-16Clinical Trial Update: Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis [Phase 1]
Phase 1 safety and tolerability study of ABBV-744 alone or in combination with oral ruxolitinib or navitoclax in adult patients with myelofi…
-
CLINICAL_TRIALS trial_result · 2025-05-25Clinical Trial Update: Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza [Phase 1]
Phase 1 blinded cross-over bioequivalence trial comparing Luitpold azacitidine with Vidaza has completed, with results posted.
-
CLINICAL_TRIALS trial_result · 2025-05-23Clinical Trial Update: Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis [Phase 2]
A Phase 2 trial comparing NS-018 to best available therapy in myelofibrosis was terminated, and results have been posted on May 23, 2025.
-
CLINICAL_TRIALS trial_result · 2025-04-27Clinical Trial Update: RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma [Phase 1, Phase 2]
A completed Phase 1/2 study evaluating everolimus (RAD001) in relapsed or refractory hematologic malignancies, including leukemia, mantle ce…
-
CLINICAL_TRIALS trial_result · 2025-04-08Clinical Trial Update: A Study to Assess Real-World Patient-Reported Outcomes With Fedratinib for Myelofibrosis Post-Ruxolitinib
A completed trial update reports real-world patient-reported outcomes for fedratinib in myelofibrosis patients who progressed or were intole…
-
CLINICAL_TRIALS trial_result · 2025-03-30Clinical Trial Update: Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MF [Phase 1, Phase 2]
This document reports the completion update of a Phase 1/2 trial evaluating the combination of ruxolitinib and pomalidomide in patients with…
-
CLINICAL_TRIALS trial_result · 2025-03-12Clinical Trial Update: A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis [Phase 2]
Phase 2 study evaluating tolerability and efficacy of navitoclax alone or in combination with ruxolitinib in myelofibrosis has completed and…
-
CLINICAL_TRIALS trial_result · 2025-03-05Clinical Trial Update: Phase 2 Study of SAR302503 in Patients With Myelofibrosis [Phase 2]
Phase 2 trial of the investigational agent SAR302503 in patients with myelofibrosis has been completed, with results summarized in the updat…
-
CLINICAL_TRIALS trial_result · 2025-03-05Clinical Trial Update: Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis [Phase 3]
This clinical trial update notes the completion of a Phase III study of SAR302503 in intermediate-2 and high-risk myelofibrosis patients.
-
CLINICAL_TRIALS trial_result · 2025-03-05Clinical Trial Update: Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib [Phase 2]
Phase II, open-label, single-arm study evaluating SAR302503 in myelofibrosis patients who were previously treated with ruxolitinib; the tria…
-
CLINICAL_TRIALS trial_result · 2025-03-05Clinical Trial Update: A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis [Phase 1, Phase 2]
A long-term Phase 1/2 clinical trial evaluating orally administered SAR302503 in patients with Myelofibrosis has completed, sponsored by Bri…